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Somatic mutations reveal asymmetric cellular 
dynamics in the early human embryo
Young Seok Ju1,2, Inigo Martincorena1, Moritz Gerstung1,3, Mia Petljak1, Ludmil B. Alexandrov1,4, Raheleh Rahbari5, 
David C. Wedge1,6, Helen R. Davies1, Manasa Ramakrishna1, Anthony Fullam1, Sancha Martin1, Christopher Alder1,  
Nikita Patel1, Steve Gamble1, Sarah O’Meara1, Dilip D. Giri7, Torril Sauer8, Sarah E. Pinder9, Colin A. Purdie10,  
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Somatic cells acquire mutations throughout the course of an 
individual’s life. Mutations occurring early in embryogenesis 
are often present in a substantial proportion of, but not all, cells 
in postnatal humans and thus have particular characteristics 
and effects1. Depending on their location in the genome and the 
proportion of cells they are present in, these mosaic mutations can 
cause a wide range of genetic disease syndromes2 and predispose 
carriers to cancer3,4. They have a high chance of being transmitted 
to offspring as de novo germline mutations and, in principle, can 
provide insights into early human embryonic cell lineages and 
their contributions to adult tissues5. Although it is known that 
gross chromosomal abnormalities are remarkably common in early 
human embryos6, our understanding of early embryonic somatic 
mutations is very limited. Here we use whole-genome sequences 
of normal blood from 241 adults to identify 163 early embryonic 
mutations. We estimate that approximately three base substitution 
mutations occur per cell per cell-doubling event in early human 
embryogenesis and these are mainly attributable to two known 
mutational signatures7. We used the mutations to reconstruct 
developmental lineages of adult cells and demonstrate that the 
two daughter cells of many early embryonic cell-doubling events 
contribute asymmetrically to adult blood at an approximately 2:1 
ratio. This study therefore provides insights into the mutation rates, 
mutational processes and developmental outcomes of cell dynamics 
that operate during early human embryogenesis.
In adult tissues, somatic mutations of early embryonic derivation 
can be distinguished from inherited polymorphisms as they will 
 generally show lower variant allele fractions (VAFs). For example, 
somatic  mutations arising in one of the two daughter cells of a ferti-
lized egg will show VAFs of approximately 25% (Fig. 1a), compared 
to approximately 50% for inherited heterozygous polymorphisms, if 
the two cells have contributed equally to the adult tissue analysed8. 
To identify early embryonic base substitutions, we analysed whole- 
genome sequences of blood samples from 279 individuals with breast 
cancer (mean  sequencing coverage 32-fold; Supplementary Table 1), 
seeking mutations with VAFs ranging from 10% to 35%. To remove 
inherited heterozygous polymorphisms that fell by chance within this 
range, we phased candidate low VAF mutations to nearby germline 
heterozygous polymorphisms (Fig. 1b; Supplementary Discussion 1). 
Substitutions present in regions with copy number variation were also 
excluded (Extended Data Fig. 1). After experimental validation by 
ultrahigh-depth targeted sequencing (median read-depth = 22,000; 
Supplementary Table 2), we identified 605 somatic base substitutions 
with accurate VAF estimates (Extended Data Fig. 2) that appeared to 
be present in only a proportion of adult blood cells.
Mutations present in a subset of white blood cells can also reflect 
the presence of neoplastic clonal expansions arising from adult hae-
matopoietic stem cells9–11. We excluded samples showing evidence 
of  neoplastic clones on the basis of the following features (Fig. 1c–e, 
Extended Data Fig. 3; Supplementary Discussion 2): many (n > 4) 
low VAF mutations; absence of the mutations in breast cancers 
from the same individuals; presence of known driver mutations for 
 haematological neoplasms (Supplementary Table 1); multiple muta-
tions showing similar VAFs (Extended Data Fig. 4). The median age of 
the 38 individuals carrying these cryptic neoplasms was 12 years higher 
than the other cases (64 versus 52 years, respectively; P = 0.00003; 
Fig. 1f), consistent with previous reports9–11. We thus obtained 
163 mosaic mutations from 241 individuals, the large majority of which 
are likely to have arisen during early human embryogenesis (Fig. 1g, 
Extended Data Fig. 5; Supplementary Table 3). From one individual, 
multiple single leukocytes were sequenced to confirm that the mutation 
was only present in a subset (Fig. 1h).
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Most mutations of early embryonic origin would be expected to be 
present in all normal tissues and not just in white blood cells. From 
13 individuals with putative early embryonic mutations (n = 21) in 
blood, we sequenced normal breast (composed of cells of  ectodermal 
and  mesodermal origins) and lymph nodes (composed of cells of 
 mesodermal origin). Consistent with their proposed embryonic  origin, 
most mutations were found in the additional normal tissues, with 
VAFs indicative of being mosaic and correlating with those in blood 
(Fig. 1i). The VAFs were generally lower in normal breast and lymph 
node than in blood, suggesting that different tissues may develop from 
slightly different subpopulations of early embryonic cells and/or that 
unequal lineage expansions occur later in development (Supplementary 
Discussion 3).
In contrast to normal tissues, which are composed of multiple 
somatic cell clones, a breast cancer derives from a single somatic 
cell. Thus an early embryonic mutation would be expected either 
to be  present in all cells of a breast cancer or in none (Fig. 1a, d, e) 
(although, in practice, the presence of contaminating non-cancer cells 
in the  cancer sample has to be corrected for; Methods). This was the 
pattern observed, with 37 mosaic mutations shared between the blood 
and the breast cancer from the same individuals, 105 non-shared and 
21 uncertain, either due to a large deletion in the relevant region of 
Lineage 1
a
White blood cells
Mosaicism
C
T
Heterozygous
polymorphism
b
DNA sequence reads
from bulk normal tissue
d
Matched breast cancer cells if tumour is derived from lineage 2
All cells are mutants
(mutation shared in cancer)
All cells are wild type
(mutation non-shared in cancer)
c
Matched breast cancer cells if tumour is derived from lineage 1
e
C>A Non-shared in cancer
Shared in cancer
Loss-of-mutation 
or indetermined
163 early embryonic
mutations 
from 241 blood samples
C>G
C>T
T>A
T>C
T>G
0.50
0
VAF
f
0 
0.5 
1.0 
20 30 40 50 60 70 80 90 
Samples without evidence of
neoplastic clones (n = 241)
Samples with evidence of
neoplastic clones 
(n = 38)
C
um
ul
at
iv
e 
fr
ac
tio
n 
of
 s
am
p
le
s
Individual age at sampling (year)
P = 2.6 × 10–5
1
0 20 40 60 80 10
0
12
0
14
0
16
0
18
0
20
0
22
0
24
0
2
0
20
40
60
80
10
0
12
0
14
0
16
0
18
0
20
0
22
0
24
0
3
0
20
40
60
80
100
120
140
160
180
4
0
20
40
60
80
100
120
140
160
180
5
0
20
40
60
80
100
120
140
160
180
6
0
20
40
60
80
100120140160
7
0
20406080100120140
8
020406080100
120
140
9
0
024
0608
0
10
0
12
0
14
0
10
0204
06
08
010
012
0
11
02
04
06
0
80
10
01
20
12 02
0
40
60
80
10
0
120
13
0
20
40
60
80
100
14
0
20
40
60
80
100
15
0
20
40
60
80
100
16
0
20
40
60
80
17
0
20
40
60
80
18
0
20
40
60
19
0
20
40
20
0
20
40
60
21
0
20
40
22
0
20
40
X
0
20
40
60
80
100
120
140
g
C
T
Early embryonic
mutation
C
T
C
T
C
T
DNA sequence reads
from bulk cancer tissue
C
T
T
580
A G C/A A A TA C T C/T G G T
130
rs17726238
A C T C/T G
130
G T T
580
A G C A A T
PD7344b 
T A G A A TBulk tissue seq. (MiSeq)
(depth 17,000x;
16.2% VAF)
Single-cell capillary sequencing
(24 mutants from 77 single cells;
mosaic; 15.6% overall VAF)
Mutant
(24 cells)
Wild type
(53 cells)
C/A
h
chr3:187,268,541 C>A 
0 0.1 0.2 0.3 0.4 0.5
0
0.1
0.2
0.3
0.4
VAF in blood tissue
V
A
F 
in
 n
on
-b
lo
od
 n
or
m
al
 t
is
su
e
Lymph node
Adjacent breast
i
Early mutation
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 >14
(max:41)
Total enrolled samples
(n = 279) 
Samples without clonal 
haematopoiesis (n = 241) 
Proportion of mutations 
non-shared in cancer
Number of early embryonic mutation candidates per sample
N
um
b
er
 o
f s
am
p
le
s
0 
50 
100 
150 
0.6 
0.7 
0.8 
0.9 
1.0 
P
rop
ortion of m
utatoins 
non-shared
 in cancer
Fertilized egg 
Lineage 2
12 yr
0.25
Wild-type
cell
Mutant
cell
Mutant
cell
Mutant
cell
DNA sequence reads
from bulk cancer tissue
Wild-type
cell
Wild-type
cell
Figure 1 | Detection of somatic mutations acquired in early human 
embryogenesis. a, Transmission of an early embryonic mutation. 
Embryonic cells (circles), their diploid genomes (black bars), and an early 
mutation (red square) are represented. b, Early embryonic mutations 
appear as somatic mosaicism in normal polyclonal tissue (for example, 
blood). c, Distribution of the numbers of early embryonic mutations 
per individual genome. The proportion of mutations non-shared with 
cancer is shown (green line). Error bars denote 95% confidence intervals 
(binomial test). d, e, Early embryonic mutations can appear as either 
absent (‘non-shared’; d) or fully clonally present (‘shared’; e) in cancer cells 
depending on the embryonic cell lineage from which the cancer is derived. 
f, The median age of individuals with evidence of neoplastic expansion in 
blood is 12 years higher than individuals without it. P value from t-test. 
g, A circos plot showing 163 early embryonic mutations identified from 
241 individuals. h, A mosaic mutation validated by single-cell sequencing. 
i, Embryonic mutations (n = 21) confirmed in non-blood normal tissues 
(breast or lymph node; n = 13).
Figure 2 | Features of early embryonic mutations. a, An example of 
an embryonic mutation non-shared with cancer. The minimal low VAF 
(2.6%) observed in the tumour ultrahigh-depth amplicon sequencing is 
consistent with a contaminating population of mutant non-neoplastic 
cells. b, An example of an embryonic mutation shared with cancer.  
The high VAF (42.1%) in the tumour ultrahigh-depth amplicon 
sequencing is consistent with a clonal mutation in cancer cells and a 
contaminating population of wild-type non-neoplastic cells. c, The 
proportion of shared mutations correlates with the VAF of mutations in 
blood.
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Figure 3 | Unequal contributions of early embryonic cells to adult 
somatic tissues. a, The VAF distribution of 163 early embryonic mutations 
in blood. Light green bars, VAFs from ultrahigh-depth amplicon 
sequencing; grey bars, VAFs from whole-genome sequencing (when 
ultrahigh-depth amplicon sequencing is not available). The expected 
distributions of VAFs (with adjustment for sensitivity of mutation 
detection) from symmetric (black line) and best-fitting asymmetric  
cell-doubling models (red line). b, A contour plot showing the 
optimization of asymmetries in cell doublings. The horizontal axis  
and vertical axis present the asymmetry levels for the first and the  
second dominant cell doublings (cell doubling of MRCA and I-1 cells  
(see Fig. 3c), respectively). Compared to the symmetric model (black 
arrow), the maximum likelihood asymmetric model (red arrow) provides  
a much better fit to the data (P = 1 × 10−40, likelihood ratio test).  
c, Maximum likelihood relative contributions of early cells to the adult 
blood cell pool (pie chart). The asymmetries of each cell doubling are 
shown using horizontal bar graphs (blue bar, significant asymmetry; 
grey bar, non-significant asymmetry). Error bars denote 95% confidence 
intervals from non-parametric bootstrapping. d, Simulation study under 
a stochastic bottleneck model according to the number of ICM founder 
cells. The relative contributions of the first four cells are shown (Methods).
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the cancer genome (n = 14) or statistical ambiguity (n = 7) (Fig. 2a, b). 
The proportion of early embryonic mutations shared between the 
blood and the cancer is predicted to change according to the stage of 
early embryonic development at which the mutation occurred, with 
mutations acquired later (and thus with lower VAF) shared less often 
(Extended Data Fig. 3a). Consistent with this expectation, embryonic 
mutations with lower VAFs in blood were shared less frequently with 
breast cancers (Fig. 2c).
These patterns of shared low VAF mutations in blood (which is of 
mesodermal origin) with normal and neoplastic breast tissue (which 
is of ectodermal origin) supports a model in which the most recent 
common ancestor (MRCA) cell of adult blood cells is the fertilized egg 
(Extended Data Figs 6, 7; Supplementary Discussion 4), or is the MRCA 
cell of all/most somatic cells, rather than an alternative model of a single 
MRCA of the blood occurring at a later stage of embryogenesis with 
very restricted subsequent fate.
The VAFs of the 163 validated early embryonic mutations in 
blood, which ranged from 45% to 1%, provided insights into the early 
 cellular dynamics of embryogenesis (Fig. 3a). If, in the large majority 
of embryos, the first two daughter cells of the MRCA cell of blood 
 contributed equally to adult blood cells (symmetric cell doubling), 
a narrow 25% VAF peak would be expected for mutations acquired 
at this stage. However, this peak was not observed, which indicates 
that  asymmetric contributions are common. To explore the basis of 
this asymmetrical contribution systematically, we generated a series 
of models of cell genealogies in which different branches  contributed 
unequally to adult blood (Methods). The asymmetry that best fitted the 
observed VAF distribution is an average, across embryos, approximately 
2:1 contribution of the first two daughter cells (cells I-1 and I-2; 
Fig. 3b, c). Moreover, this approximately 2:1 asymmetric cell contribu-
tion appears to extend to some cells of the second cell generation (cells 
II-1 and II-2; Fig. 3b, c) and possibly of the third cell generation. The 
model with unequal contributions was clearly superior to a null model 
of strictly symmetric cell doublings (P = 1 × 10−40, likelihood ratio test, 
Fig. 3a, b). This frequent unequal contribution of the earliest human 
embryonic cells to adult somatic tissues is consistent with previous 
indications from studies of mouse development5,12–15.
Two classes of biological mechanism may underlie these asymme-
trical contributions. One daughter cell and its progeny may  contribute 
more because they intrinsically have a lower death rate, a higher 
proliferation rate and/or a preference for contributing to embryonic 
compared to extra-embryonic tissues14–16. Indeed, studies in mice 
have shown that cells separated from two-cell embryos have different 
intrinsic developmental potentials16,17. Alternatively, the stochastic con-
sequences of a bottleneck in early embryo development could be the 
source of the asymmetry. In the early blastocyst-stage human embryo, 
composed of 50–100 cells (blastomeres), only the minority of cells 
(< 20) present in the inner cell mass (ICM) eventually contribute 
to adult somatic tissues18. Under a model in which a small number 
(< 20) of ICM founder cells are selected at random from a  blastocyst 
composed of many (> 50) blastomeres and most founder cells 
 contribute to adult cell populations, it is likely that the progeny of the 
first two embryonic cells will, in many embryos, be selected in  unequal 
proportions, as recently observed in mice19. Simulations indicate that 
stochastic allocation of early human embryonic cells into the ICM 
results in levels of asymmetric contribution similar to those observed 
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Figure 4 | Rates and mutational spectra of early embryonic mutations. 
a, Estimates of early embryonic mutation rates. Best-fitting asymmetric 
model (top), symmetric model (middle) and family study (bottom)  
provide similar rate. Broken lines represent 95% confidence intervals  
from bootstrapping (Methods). b, Early embryonic mutations obtained 
from 3 large families. Each mutation is shown with a number (index) 
inside the white rectangles or circles in the pedigrees. Sequencing reads 
are shown for one of the mutations (5) in family 569. c, Similar mutational 
spectra7 obtained from 163 early embryonic mutations and from 747  
de novo mutations reported previously20. Horizontal axes, 96 mutation 
types (Methods); vertical axes, proportion of mutations.
in this study (Fig. 3d, Extended Data Fig. 8; Methods). Assuming the 
stochastic hypothesis is correct, we estimate that around 10 ICM 
founder cells give rise to blood (Fig. 3d).
Using the asymmetric cell-doubling model, we estimated a rate of 
2.8 substitution mutations per early embryonic cell per cell doubling 
(Fig. 4a; 95% confidence interval 2.4–3.3; Supplementary Discussion 5). 
A similar rate was obtained under a simple model without asymmetric 
contributions (Fig. 4a). This early embryonic mutation rate is compa-
rable to, but may be slightly higher than, the germline mutation rate 
(~ 0.2–1.4 mutations per diploid genome per cell division)20. However, 
our mutation rate per cell doubling may not equate to the rate per cell 
division because early embryonic development may involve cell loss, 
perhaps due to fatal chromosomal aberrations6, and thus each cell- 
doubling may entail more than a single cell division. If so, the mutation 
rate per cell per cell division will be lower than the estimated rate per 
cell per cell doubling. We validated the early embryonic mutation rate 
using whole-genome sequences of bloods from three large families20 
(Fig. 4b). We found seven substitution mutations in children that were 
not present in their parents that had features described above of early 
embryonic mutations (Extended Data Fig. 9) and obtained a similar 
early embryonic mutation rate of 2.8 per cell per cell doubling (95% 
Poisson confidence interval 1.1–5.8; Fig. 4a). The mutational spectrum 
of early embryonic mutations was predominantly C:G> T:A (42.9%), 
T:A> C:G (25.1%) and C:G> A:T substitutions (16.6%), similar to that 
of de novo germline mutations20 (Fig. 4c) and is probably caused by 
multiple endogenous mutagenic processes (Extended Data Fig. 10; 
Supplementary Discussion 6).
Very few early post-zygotic mutations have been reported21–23. We 
identified 163 mosaic mutations from 241 individuals which exhibit 
the characteristics of early embryonic origin (although we cannot 
exclude a small residual set of other types of mutations). With the 
accurate VAF information and the proportion of mutations shared with 
 cancer, we explored developmental processes. An average of around 2:1 
 asymmetry of early human embryonic cells in their contributions to 
adult tissues (at least to blood) was revealed, providing insight into the 
fates of cells at early developmental stages. However, our conclusion is 
based on statistical reconstructions and requires corroboration through 
larger studies, particularly those involving multiple tissues. The results 
also allowed estimation of the mutation rate and characterization of the 
mutational processes underlying base substitutions in the early human 
embryo, which appear comparable to those in mouse embryogenesis5 
and human adult somatic tissues18,24,25. The early human embryonic 
mutation rate estimated here indicates that, using similar methods to 
those introduced in mice5, reconstruction of cell lineage trees using 
somatic mutations should be possible in humans.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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METHODS
Data reporting. No statistical methods were used to predetermine sample size. 
The experiments were not randomized and the investigators were not blinded to 
allocation during experiments and outcome assessment.
Samples and sequencing data. For initial discovery of early embryonic  mutations, 
we analysed whole-genome sequencing data from 304 blood samples from 
patients with breast cancer that were sequenced as normal controls for the ICGC 
(International Cancer Genome Consortium) breast cancer study26. Genomic DNA 
was extracted from bulk white-blood cells collected from fresh peripheral bloods. 
Matched breast cancer samples for all the individuals were also analysed in parallel. 
Of these, 25 samples with putative DNA contamination were removed (see below 
for more details), and 279 samples were used for the detection of early  embryonic 
mutations (the sample information is available in Supplementary Table 1). 
For  validating the early embryonic mutation rates, we also used whole-genome 
sequencing data from 19 blood samples from 3 families20. For confirmation of early 
embryonic mutations in non-blood normal tissues, we extracted genomic DNA 
from FFPE (formalin-fixed and paraffin embedded) lymph nodes and normal 
breast tissue surgically resected during mastectomy procedures (sample history is 
available in Supplementary Table 1). The whole-genome sequencing data analysed 
in this study were generated using Illumina platforms (either Genome Analyzer 
or HiSeq 2000). Sequencing reads were aligned to human reference genome build 
37 (GRCh37) using the BWA alignment tool27. All PCR duplicate reads were 
removed.
DNA contamination control. We thoroughly checked for possible sources of 
DNA contamination: tumour-normal swap; matched tumour DNA  contamination 
in blood; and cross-contamination with DNA from other individuals. Cases of 
tumour-normal sample swap were identified by examining the presence of 
genome-wide copy number variations in the putative normal samples. Cases of 
matched tumour DNA contamination were identified by examining the VAFs 
in the blood sequencing data for the somatic substitution variants identified in 
the matched cancer using CaVEMan software28 (available at https://github.com/
cancerit/CaVEMan/). When the average VAF of cancer-specific substitutions was 
more than 1% in a blood sample, we regarded the blood sample to be  contaminated 
by a matched tumour DNA sample. Finally, for each sample, the level of DNA 
cross-contamination with tissue from other individuals was estimated as described 
previously29.
Variant calling. VarScan2 software30 was used for initial early embryonic  variant 
calling. Input vcf files were generated from whole-genome sequencing bam 
files using ‘samtools’31 ‘mpileup’ with three options -q 20, -Q 20 and -B. Then 
VarScan2 ‘somatic’ was applied to blood samples with matched tumour  samples as 
reference. Three options were applied for the VarScan2 running, –min-reads2 4, 
–min-ave-qual 20, and –strand-filter. We selected substitution  variants with 
VAFs ranging from 0.1 to 0.35 as putative early embryonic mutations. We 
removed putative  mutations near germline indels (within 5 bp), because these 
are mostly false  positives due to mismapping. Putative mutations likely to 
be sequencing artefacts and/or germline polymorphisms were removed if the 
 variants were also present in the unmatched blood samples analysed in this 
study, or were known germline polymorphisms with at least 1% population allele 
 frequency identified from the 1000 Genomes Project (November 2013), or deposi-
ted in dbSNP (v138). We removed putative variants in segmental duplications, 
 simple repeats, repetitive sequences (RepeatMasker) and homopolymer sequences 
in the human reference genome (downloaded from UCSC genome browser, 
http://genome.ucsc.edu/).
Substitution phasing. We phased the putative embryonic variants to  heterozygous 
germline substitutions using sequences from whole-genome sequencing as described 
previously29,32. For more conservative phasing, we did not use sequences at the 4 bp 
extremes of each read, where substitutions and indels are not well called. From blood 
whole-genome sequencing data, we classified the putative variants into four groups, 
‘phasing not available’, ‘mixed pattern’, ‘no evidence of  subclonality’ and ‘subclonal’ 
using criteria as  follows: (1) phasing not available: no  available read covering both 
the mutation and the heterozygous single nucleotide polymorphism (SNP) in the 
vicinity. (2) Mixed pattern: the putative variant is present in both the bi-allelic hap-
lotypes of  heterozygote SNPs. (3) No evidence of subclonality: the putative variant 
is  completely and exclusively present on one of the two haplotypes of heterozygote 
SNPs. (4) Subclonal: the putative variant is present in a fraction of one of the two 
haplotypes of heterozygote SNPs. The variant is not present on the other haplotype.
Putative mutations categorized other than subclonal were removed. For the 
 subclonal mutations, we estimated the probability of false subclonality due to 
sequencing errors. For this calculation, we counted only informative reads, which 
were participating in the phasing: reads covering the putative mutation locus and 
one of the alleles of the inherited heterozygous SNP in which the early mutation 
is linked.
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Q1 and Q2 are sequencing error rates of the bases at the putative mutation and 
the heterozygote SNP loci, respectively; i represents each of the informative reads 
harbouring the mutant base at the early embryonic mutation site; V is the total 
number of informative reads with the mutant base; likewise, j represents each of 
the informative reads harbouring a wild-type base at the early embryonic  mutation 
site and W is the total number of such reads. When there was more than one 
heterozygous SNP site that was used for phasing, we  calculated a string of phasing 
error rates (Perror) from every SNP site and multiplied them to obtain an overall 
phasing error rate.
Substitutions at regions of copy number variation. We removed any  putative 
mutation if it was located in a region with copy number higher than two. We 
 isolated potential copy number variation of each genome using both intra- 
sample and inter-sample methods. For the intra-sample method, we calculated 
the  standard deviation of read-depth from all (~ 2 million) germline hetero-
zygous SNP sites from every normal whole-genome sequencing dataset. When 
the local coverage of an early embryonic mutation candidate was higher than 
the 95% percentile (that is, local depth is greater than genome-wide mean WGS 
 coverage + 1.645 × s.d.; for example, the cutoff is approximately 46× in typical 
30× coverage sequencing) of the sample, we considered the site was possibly 
duplicated thus removed from our further analyses (Extended Data Fig. 1a). For 
the inter-sample method, we clustered the normalized normal whole-genome 
sequencing (WGS) read counts of a candidate region (from 1 kb upstream of 
the mutation site to 1 kb downstream) from all the samples included in this study. 
If the normalized copy number of the target sample was either an outlier in the 
clustering or was two-times higher than expected from genome-wide average, 
the mutation candidate was considered to be located in a germline copy number 
variant region and was thus filtered out (Extended Data Fig. 1b, c).
Mutations shared by the paired tumour tissue. Then we investigated whether 
the early embryonic mutation candidates were also present in cells of the breast 
cancer from the same individual. This is not always straightforward because 
(1) whole-genome sequencing of cancer tissue generates a mixture of sequences 
from cancer and contaminating normal cells and (2) copy number changes are 
quite frequent in the cancer genome. Using the ASCAT algorithm33, based on 
analysis of the variant allele fraction for heterozygous germline SNPs for regions 
departing from diploidy in the tumour genome, we estimated the tumour cell 
fraction (‘f  ’ in the formula below), ploidy of cancer genome (‘p’) and local 
A (major) and B (minor) allele copy numbers (‘a’ and ‘b’, respectively). Each mutant 
allele was previously phased to either A or B allele nearby. Using these estimates, we 
built a model for the expected number of reads (N) supporting the mutant allele in 
paired-cancer genome sequencing in three different scenarios:
(I) The mutant allele is not shared (and approximate 95% binomial confidence 
interval),
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According to these models, we assigned our mutation to four groups: ‘non-shared’ 
(model I), ‘shared’ (model II or III), ‘loss-of-mutant allele’ (when the mutant allele 
is phased to B allele and b is 0) and ‘uncertain’ (when more than 1 model could 
explain or no convincing ASCAT result is available for the sample).
Visual inspection. We visually inspected all of the candidate embryonic 
 mutations using the Integrative Genomic Viewer34 and JBrowse35. We confirmed 
that genomic regions with putative embryonic mutations were not in sequences 
with evidence of artefacts and thus that any putative mutation was supported by 
high-quality sequencing reads. Two examples of early embryonic mutations are 
shown in Fig. 2a, b.
Validation by MiSeq amplicon sequencing. We tried to validate all the 
 putative early embryonic mutation sites. We designed 959 pairs of PCR primers 
(Supplementary Table 2) for 863 candidate early mutations to make amplicons 
for the putative mutation sites along with the nearby heterozygote SNPs used 
for phasing from the blood and paired-cancer DNA samples of the individual 
harbouring the putative mutation. After clean-up using ExoSAP-IT (Affymetrix 
Inc.), all amplicons from blood and matched cancer tissues were separately pooled 
and sequenced by 2 × 250 bp MiSeq sequencing (Illumina, Inc.) two runs per pool, 
expecting > 1,000× coverage per amplicon (median read-depth = 22,000× ). 
Because the read-depth is very high in amplicon sequencing, we could obtain a 
much more precise VAF of the putative embryonic mutation along with accurate 
phasing to the germline heterozygote substitution. The VAFs for germline hete-
rozygote substitutions in non-repetitive genome regions showed a clear peak at 
0.5 (Extended Data Fig. 2a). To estimate the extent to which the amplification 
process biased the VAFs, we fitted a beta-binomial distribution with mean 0.5 and 
dispersion to the numbers of reads supporting both alleles in heterozygous SNPs 
(which have an expected VAF of 0.5). This confirmed that the additional uncer-
tainty introduced by amplifications was very small (θ = 223.88;  overdispersion, 
ρ = 1 / (1 + θ) = 0.004). This estimate of the overdispersion was used in the 
 maximum likelihood asymmetric models. The targeted amplicon sequencing 
showed high precision in the assessment of the VAF of a mutation (Extended 
Data Fig. 2b). The MiSeq validation experiment confirmed that the candidate 
mutations were not sequencing artefacts nor inherited mutations both from the 
resulting VAFs (ranged from 0.01 to < 0.5, mostly < 0.35) and from phasing to the 
local heterozygous SNP. From this validation study, we found that there is a clear 
linear relationship between phasing error rates (as calculated above) and validation 
success rate (data not shown). We could not create amplicons from some mutation 
candidates owing to lack of DNA samples or unsuccessful PCR reactions. Of these, 
we rescued 14 early embryonic mutations because they are likely to be true on the 
basis of phasing error probability in whole-genome sequencing (Supplementary 
Table 3).
Validation using single cells. From the blood of one individual (PD7344) we 
sorted 144 granulocytes. Genomic DNA of each single cell was extracted and 
whole-genome amplified (WGA) using the REPLI-g Single Cell Kit (Qiagen, Inc.), 
following the manufacturer’s protocol. Of the 144 single cells, 131 provided sub-
stantial amounts of WGA DNA. PCR amplicons were produced targeting the early 
embryonic substitutions in the sample (chr3:187268541, C> A). PCR reactions 
were successful from 118 WGA DNAs. After clean-up of the 118 PCR products, 
capillary sequencing was performed. Of these, 41 showed allelic dropout of the 
DNA haplotype on which the embryonic mutation was present (that is, absence 
of the T allele of rs17726238) and thus were not further considered. Among 
the 77 informative amplicon sequencing results, 24 showed clear evidence of the 
 embryonic substitutions as shown Fig. 1h.
Late somatic mutations due to clonal haematopoiesis. Age-related clonal hae-
matopoiesis is quite common, and observed in more than 10% of persons older 
than 65 years old9–11. Like mutations that have occurred in the very early embryo, 
these late mutations appear to be subclonal (mosaic) in adult blood. However, such 
late mutations are rarely shared with the breast cancer sample from the same 
 individual because the vast majority of them occurred after formation of the three 
germ layers, specifically in the mesodermal lineage. In addition, late clonal 
 expansions in the blood invariably carry a large number of co-clonal mutations 
accumulated throughout life36, and so many subclonal mutations with similar VAFs 
are detected together in the blood sample. In this study, we found that each blood 
sample harbours a median of 1 validated phased subclonal mutation. According 
to their distribution (Fig. 1c), we regarded 31 samples with at least 5 validated 
subclonal mutations as outlier samples, defined as deviating from the median value 
by more than twice the interquartile range. Consistent with the hypothetical 
 presence of late clonal expansions in these outlier samples, the proportion of non-
shared mutations abruptly increases from this point (Fig. 1c). Furthermore, we 
searched 72 cancer genes (gene list is available in Supplementary Table 1) that have 
been reported to drive clonal haematopoiesis9–11 for low VAF somatic mutations 
(supported by at least 3 mismatches) and identified eight samples with mutations 
in DNMT3A, ASXL1, JAK2, PTPN11 and CBL genes. Of these, four samples were 
found among the 31 outlier samples. Conservatively, the remaining four samples 
were also classified as containing clonal haematopoiesis, despite the small number 
of mutations found in them, and therefore removed from downstream analyses. 
Finally, we assessed whether mutation candidates obtained from each sample 
showed significantly similar VAFs to each other compared to the other samples, 
indicating that those mutations may be present in same blood clone, and thus 
filtered out three additional samples. Indeed, from the 38 filtered samples, we 
observe that mutations have more similar VAF to the other mutations in the same 
sample (calculated by /VAF VAFi , where i represents each mutation in the sample) 
compared to the mutations in samples with 2–4 mutations (Extended Data Fig. 4). 
As a result, out of the total 279 samples, we classify 241 samples as having no 
 evidence of clonal haematopoiesis, and therefore informative for detecting 
 embryonic mutations (Extended Data Fig. 5).
Finally, we assessed whether matched tumour sequences showed evidence of 
the mutant allele with significantly higher VAFs than background  sequencing error 
rate levels (Extended Data Fig. 2c). This would be expected, because  normal cells 
are always present in cancer samples and a fraction of the normal cells would carry 
the mutant allele if a mutation had a truly embryonic origin. Fifteen  candidate 
mutations, from which the VAFs in the matched cancer are not higher than 
 background, were removed through this step. After application of all filters, we 
identified 163 likely early embryonic mutations from 241 samples.
Asymmetry in early cell doublings. In order to fit different lineage models to 
the VAF of embryonic mutations, we used a likelihood approach. If read counts 
were fully independent, allelic counts from each mutation could be modelled as 
being binomially distributed. However, to account for the overdispersion caused 
by the amplification process before library preparation, we assume allelic counts 
to be beta-binomially distributed. As shown above, we estimated the overdis-
persion parameter θ = 223.9 (95% confidence interval, 201–248). Over 98.7% of 
hetero zygous SNPs had a VAF in the range [0.4, 0.6] in the re-sequencing dataset 
(Extended Data Fig. 2a).
If the first cell doubling gives rise to two daughter cells that contribute equal 
numbers of cells to the adult (or the adult blood population), the doubling is 
 considered symmetrical. Otherwise, the doubling is considered asymmetrical, 
with one cell contributing a fraction α 1 of the cells in the adult and the other 
cell 1−α 1. Assuming that embryonic mutations are heterozygous, the expected 
VAF of a mutation occurring in branch 1 of the lineage is 0.5 × α 1 and in branch 
2 is 0.5 × (1−α 1). The same applies to any doubling in the lineage, with the two 
 daughter cells contributing α n and 1−α n, relative to the contribution of the mother 
cell (n). This allows us to calculate the expected VAFs in the adult cell population 
for  mutations occurring at each branch of the model lineage tree (vb).
For each embryonic mutation, j, we observe the number of mutant reads (mj) 
and the total coverage at the site (cj). The likelihood of observing a given mutation 
under a particular lineage model requires integration of the likelihood of  observing 
the mutation under each branch of the lineage, considering also the mutation 
rate at each branch and the sensitivity to mutations from each branch. In other 
words, the VAFs are fitted to a mixture model, as mutations could have occurred 
at any branch in the tree. The total log-likelihood of the model is the sum of the 
log-likelihoods from all mutations,
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Where P(m,c,v,θ) denotes the beta-binomial probability distribution function, N 
is the total number of mutations in the dataset (N = 163), B is the total number 
of branches in the model and rb is the (relative) mutation rate of the branch. sb is 
the (relative) sensitivity to mutations from the branch, which is a function of the 
expected VAF of mutations from the branch (vb). Sensitivity as a function of VAF 
is calculated as described in the section below.
Statistical comparison of models of increasing complexity. To evaluate whether 
a lineage with one asymmetric doubling fits the data significantly better than a 
 symmetric model, we obtained the maximum likelihood estimate for α n from 
each of the 15 doublings from the first 4 cell generations, while keeping all other 
 doublings symmetrical. The best 1-asymmetric-rate model is tested against the 
symmetric model with a likelihood ratio test with 1 degree of freedom, and 
the P value is subjected to Bonferroni multiple testing correction to account for 
the 15 models evaluated. This revealed that a lineage in which the first doubling 
is asymmetric with α 1 ≈ 0.61 fits the data much better than a symmetric model 
(LL0 = –1,444.4, LL1 = –1,366.3 (LL, log-likelihood), P < 10−16).
To test models with additional asymmetric rates, we used a heuristic approach. 
Instead of testing all possible combinations of asymmetric rates, we tested the effect 
of adding an extra asymmetric rate to the previous model (14 alternative models). 
The best model included asymmetry in the cell doubling of the  dominant  daughter 
cell in the first cell doubling (LL1 = –1,366.3, LL2 = –1,349.102, Bonferroni-
corrected P = 3.1 × 10−8). The same approach was used to find a better model 
with three and four asymmetric doublings. The best model with three  asymmetric 
doublings is only marginally better than the best model with two asymmetric 
doublings (LL3 = − 1,344.784, Bonferroni-corrected P = 0.021). More complex 
models provided no significantly improved fits to the data.
In order to evaluate whether other asymmetric lineages with two or three 
asymmetric rates could provide better fits, we exhaustively calculated the 
 maximum-likelihood values of all possible lineages with two or three asymmetric 
doublings in the first four cell-generations. No model provided a better fit to the 
ones found by the heuristic approach. This analysis strongly supports a lineage 
with at least two asymmetric rates (first and second branches).
The confidence intervals shown in Fig. 3c were calculated by non-parametric 
bootstrapping (that is, resampling the original data with replacement) followed 
by numerical search of the maximum likelihood values of the top seven rates in 
the lineage.
Estimating the average mutation rate from asymmetric lineage models. 
Assuming a given lineage model, a global estimate for the average mutation rate 
per genome per doubling in the early embryo can be obtained with the following 
equation:
∑ =
N
S sb b1
N is the total number of embryonic mutations detected (N = 163), S is the number 
of samples studied (S = 241) and sb is the sensitivity to detect a mutation from 
a particular branch of the lineage tree. Further, an approximate estimate of the 
average mutation rate at different cell generations could be obtained using an 
expectation–maximization (EM) algorithm. These estimates may be more robust 
against possible contamination from neoplastic expansions at very low VAFs than 
the global estimate above.
Assuming a particular lineage, the relative probability (expectation step) of a 
mutation (j) coming from one particular branch (b) is given by:
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where P(m, c, v, θ) denotes the beta-binomial probability distribution function. 
In the first iteration of the EM algorithm, the mutation rate (rj) of all branches 
is  considered identical. The number of mutations estimated to come from each 
branch is then calculated as the sum of these probabilities across all mutations:
∑=
=
N pb
j
N
b j
1
,
Nb is then used to update the mutation rate per branch (maximization step). And 
these two steps are iterated until convergence, obtaining an improved fit to the 
data and estimates of the mutation rates per branch. To constrain the parameters 
of the model, the rates of all branches from the same cell-generation are  maintained 
identical during the EM algorithm. Confidence intervals were obtained by boot-
strapping (400 replicates). Importantly, allowing the mutation rates of the first 
three cell generations to vary freely with respect to the rest of the lineage (values 
shown in main text, Fig. 4a), does not significantly improve the fit of the model 
(LL = –1,347.0 as opposed to LL2, P value = 0.24, 3 degrees of freedom).
Simulation of sensitivity. We estimated the sensitivity for early embryonic 
 mutations from simulation studies. The sensitivity will be dependent on the target 
VAF (ρ) of early mutations. First, we randomly generated 1,000 in silico embryonic 
mutations genome-wide. In silico mutations within known gaps of the human 
 reference genome were removed and replaced with newly generated mutations. 
Note that this means that sensitivity, and so the mutation rates, estimated in our 
study exclude mutations present in gaps, which approximately correspond to 10% 
of the human genome. Next, under 21 different theoretical VAFs (ρ; 0.016, 0.028, 
0.031, 0.056, 0.063, 0.083, 0.111, 0.125, 0.139, 0.167, 0.194, 0.222, 0.250, 0.278, 
0.306, 0.333, 0.361, 0.389, 0.417, 0.444, 0.472), we queried how many could be 
detected on average from the whole-genome sequences of 241 samples. The same 
filtration steps for real mutation candidates were applied for the in silico  mutations: 
if mutations are found in 1000 Genomes Project dataset, dbSNP  variation, 
 segmental duplications, simple repeats, repetitive sequences by RepeatMasker, 
homopolymers, and potential copy number gain regions, we regarded these 
 mutations as undetectable. Then, for each potentially detectable in-silico  mutation, 
and under several given ρ, we calculated the fraction of  mutations that could be 
successfully detected and successfully phased to at least one heterozygous SNP 
nearby in each individual WGS.
ρ ρ ρ| = | × |P P P(observed ) (detection ) (phasing )
where P(detection |  ρ) is the probability of a mutation having a sufficient number 
of reads supporting the mutant allele (at least 4, or the cut-off value in this study) 
and a VAF within the range considered in the discovery phase of this study (from 
10% to 35%). Likewise, P(phasing |  ρ) represents the probability of successfully 
phasing a mutation to the heterozygous SNP nearby. We calculated P(detection |  ρ) 
and P(phasing |  ρ) as below:
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∏
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where the roundup() and roundoff() functions round to the higher or the 
 closest integer number, respectively. D is the read-depth of each detectable 
in silico  mutation site, N represents the total number of heterozygous SNPs that 
are available for phasing, i is each of the heterozygote SNPs and Si is number of 
reads spanning both a mutation locus and the heterozygous SNP. For simplicity 
of simulation, we assumed all the bases have a good base quality (that is, Phred 
score > 20). Finally, we added all probabilities, P(observed |  ρ), obtained from an 
individual given ρ. When ρ is fixed, P(observed |  ρ) correlates with read-depth 
of blood whole-genome sequencing, and the regression line was obtained using 
Loess regression. We obtained our sensitivity estimates for the 21 different ρ  values 
using this approach and a simulated coverage of 32-fold coverage (median  coverage 
for 241 blood samples). For example, 4.41% of the 1,000 in silico mutations with 
ρ = 0.25 were detectable when whole-genome sequencing coverage was 32× 
(Extended Data Fig. 5e).
A stochastic model of embryoblast formation. In the maximum likelihood 
 fitting of lineage models described above, a single lineage tree was fitted to the 
data from multiple different individuals. The resulting lineage intends to be a 
merely  descriptive representation of the average contribution of different cells 
across embryos. The model implicitly assumes that the same asymmetric lineage 
describes all patients and that the first divisions of the embryo follow a largely 
constant pattern across individuals. It remains unclear whether early embryonic 
development in viable embryos under physiological conditions follows a strict 
plan in humans or whether there is extensive variation between individuals, as 
observed in mouse19. In the presence of extensive variation in the early lineage 
across embryos, the asymmetry rates estimated using a constant lineage should 
be interpreted with caution.
Interestingly, extensive asymmetry in the contribution of the first cells of the 
embryo to the adult cell pool can also emerge under more stochastic models of 
embryo development. As a proof-of-principle, here we show how a bottleneck in 
the pre-implantation embryo, in which only a randomly selected subset of cells 
contributes to the final somatic tissues, can give rise to extensive asymmetry in the 
contribution of the first few cells of the embryo to the adult cell pool, not dissimilar 
to the general patterns observed in this study.
All final embryonic tissues are thought to derive from a fraction of cells in the 
blastocyst termed the inner cell mass (ICM), whereas the rest of the blastocyst (the 
trophoblast) will form the placenta and other extra-embryonic supporting tissues, 
and will not contribute to the adult cell pool. In mice, this separation is thought to 
involve about 12 ICM cells gravitating at the centre of the blastocyst at the 32-cell 
stage37. This imposes a significant bottleneck to the contribution of the first few 
cells in the embryo to the adult cell pool. Let us consider a simple bottleneck model 
in which a completely random subset of l cells from the n-cell stage embryo is 
selected to form the adult cell pool. If there were m cells carrying an early somatic 
mutation out of a total of n, the probability to subselecting k in a draw of l cells is 
given by the hypergeometric distribution. This is to be multiplied by the probability 
that m cells are mutated owing to early germline mutations. Without a bottleneck, 
variant alleles would only be expected at powers of 1/2, with intensities following an 
1/f power law owing to the increase in the number of cells with every cell doubling. 
Hence the probability of selecting k mutated cells out of a total n cells is given by:
=
∑ = = − ×=
−
−
P k l n
P k l m w n
( ; , )
( ; , 2 , 2 ) 2
const
i
n i i i
0
(log )2
1
where ‘const’ is a normalization constant and P(k; l, m, w) denotes the hyper-
geometric probability distribution function. Note that this distribution has support 
on VAF k/l, rather than 1/2i. The latter is approached in the limit that l = n, that 
is, all cells would propagate to the final somatic tissue (Extended Data Fig. 8a). 
The overall probability of observing mutations at a given VAF v = k / l is then to 
be multiplied by the sensitivity S(v) to detect mutation a given frequency, and the 
additional dispersion arising from detecting mutations on a finite number of x 
sequencing reads at a given coverage c, modelled by a beta-binomial sampling 
model, as described in the deterministic modelling used in the previous sections.
ρ
=
∑ / = /p x c l n
P k l n S k l P x p k l c
( ; , , )
( ; , ) ( ) ( ; , , )
const
(1)k
where P(x; p, c, ρ) denotes the beta-binomial probability distribution function; the 
dispersion ρ is inferred from heterozygous SNPs and taken to be ρ = 1 / (1 + θ) = 
0.004 with θ = 223.9 as defined above.
We may hence fit the likelihood in equation (1) to the observed data, knowing 
the number of mutated reads x and coverage c for each patient, given the number 
of ICM cells l and cells n. The maximum likelihood is obtained for l = 11 ICM cells 
separating after six generations, or n = 64 cells (Extended Data Fig. 8b), although 
there are many solutions with similar likelihood.
From equation (1), an estimate of the overall histogram P(v; l, n) over VAF v for 
fixed l and n can be computed as the average over all data points i with coverage ci:
ρ
=
∑ =P v l n
P x vc c l n
N
( ; , )
( ; , , , )i i i
where N = 163 is the number of observations and | vci| indicates a rounding to 
integer numbers. Using a Bayesian approach, assuming a uniform prior P(n) on 
the number of cell generations at which ICM commitment occurs ranging from 
n = 8 to 256 (at powers of 2), and similarly a uniform P(l) on the number of ICM 
cells ranging from l = 5 to 32, allows for computing the posterior probability of 
the observed data as:
∑=P v P v l n P l P n( ) ( ; , ) ( ) ( )
n l,
The result is shown in Extended Data Fig. 8c. This model shows how a simple 
random selection of a subset of the cells in the early embryo can lead to substantial 
asymmetries in the contribution of the first few cells in the embryo to the final adult 
cell pool. We note that this represents one extreme of possible combined deter-
ministic and stochastic scenarios. It remains unclear to what extent viable embryos 
under physiological conditions follow a tightly predetermined developmental plan 
or whether largely stochastic processes dominate before the formation of the first 
structures in the blastocyst. The available data cannot distinguish between these 
models, but we anticipate that more detailed analyses of early embryonic somatic 
mutations could shed some light on this question. In particular, deterministic 
 models predict that all individuals will share a very similar lineage pattern, whereas 
stochastic models predict largely different early lineages among individuals.
Family analyses. Genomic DNA was extracted from peripheral blood of 19 
 individuals from three large families. From the whole-genome sequences 
(median read-depth = 25× ), we detected subclonal substitutions in 13 children 
using  identical methods for the blood tissues of 241 breast cancer patients, that is, 
DNA contamination control, variant calling, phasing to nearby heterozygous SNP, 
assessment of copy number of the mutation loci, and visual inspection as described 
above. We detected 7 early embryonic mutations (Extended Data Fig. 9), which 
were subclonal and not shared by the parents or any siblings, therefore these are 
highly likely to be post-zygotic mutations which occurred at the early embryonic 
stages of a specific child.
We calculated the rate of early mutations from families (Rfamily) as below:
α
=
/
/
R
R
N S
N S
family family family
where R is the overall average early mutation rate (2.8 mutations per cell per cell 
generation), N is the number of mutations (n = 163) and S is the total sample 
size (n = 241). Likewise, Nfamily is the number of mutations (n = 7) identified 
from family data and Sfamily is the total number of children analysed (n = 13). 
α is relative sensitivity of early mutations in family data, which must be less than 
1 because sequencing coverage is around 7× coverage lower in families (25× ) 
than the unrelated 241 blood samples (32× ). The simulation of sensitivity (shown 
above) suggests that α is 0.796. A Poisson Exant test was used to calculate the 95% 
confidence interval of Rfamily.
Detecting contributions of mutational signatures. Mutational signatures were 
detected by refitting of previously identified and validated consensus signatures of 
mutational processes (http://cancer.sanger.ac.uk/cosmic/signatures). All possible 
combinations of at least seven mutational signatures were evaluated by minimizing 
the constrained linear function:
∑−
≥ =
M iEiSmin ( )
Ei i
N
0 1
Here, M and Si represent vectors with 96 components corresponding to the six 
types of single nucleotide variants and their immediate sequencing context and 
Ei is a non-negative scalar reflecting the number of mutations contributed by this 
signature (or exposure). N reflects the number of signatures being re-fitted and all 
possible combinations of consensus mutational signatures for N between 1 and 7 
were examined, resulting in 2,804,011 solutions. Model selection framework based 
on Akaike information criterion was applied to these solutions to select the optimal 
decomposition of mutational signatures. The analysis revealed that signature 1 and 
signature 5 best describe the set of embryonic mutations (Extended Data Fig. 10a). 
Including any other mutational signature did not improve the explanation of the 
set of embryonic mutations.
Data availability. Whole-genome sequence data have been deposited in the 
European Genome-Phenome Archive (EGA; https://www.ebi.ac.uk/ega/home) 
under overarching accession number EGAS00001001178. The data that support 
the findings of this study are available on request from the corresponding author.
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Extended Data Figure 1 | Filters to exclude mutation candidates in 
regions with copy number variation. a, For every blood sample, we 
assessed the distribution of coverage of around 3 million inherited SNP 
loci. Using this distribution, we determined a cut-off value that is used 
for inter-sample CNV filtering (see Methods). In the case of PD3989b 
shown in the figure, candidate mutation loci with > 51× coverage were 
considered to be located on copy number gain thus removed. b, An 
example of inter-sample CNV filtering (see Methods). Normalized 
coverage for chr11:14,446,619 region of PD4116b is located in the normal 
copy number (CN = 2) cluster. c, Copy number gain was identified in 
a candidate mutation locus (chr6:285,671) from PD4116b by the inter-
sample CNV filtering method. Therefore, this mutation candidate was 
removed from further downstream analyses.
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Extended Data Figure 2 | Features of ultrahigh-depth targeted 
amplicon sequencing used for validation. a, Estimation of the effect 
of potential PCR allelic bias from targeted amplicon sequencing. Using 
inherited heterozygous SNP sites that were PCR amplified and ultra-
deep sequenced, we assessed potential PCR bias (that is, preferential 
amplification of one allele compared to the other): the distribution of 
VAFs was broader than expected from a binomial distribution (theoretical 
maximum), but the PCR bias was not substantial as a clear peak at 
VAF = 0.5 was present. The estimated overdispersion level (theta value 
in beta-binomial distribution) was 223.88. The estimate was used in the 
simulation studies for assessment of cell-doubling asymmetry in early 
embryogenesis (see Methods for more details). b, High precision of 
ultrahigh-depth amplicon sequencing in assessment of VAF of a mutation. 
For the 14 early embryonic mutations, we quantified their VAFs from the 
second blood samples using the same strategy (that is, PCR amplification 
and deep sequencing). The VAF estimates from the first and the second 
sequencings were highly correlated. c, Background error rate of targeted 
amplicon sequencing (see Methods). The background mutation rate 
showed sequence context dependency. Error bars denote 2× interquartile 
range. We used these background mutation rates in a filtering step.
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Extended Data Figure 3 | Features of a blood sample with a neoplastic 
clonal expansion in the blood. a, This hypothetical scenario illustrates the 
expectation in a normal blood sample when there is no obvious neoplastic 
clonal expansion. Each white-filled black circle represents an embryonic 
cell. White-filled red and red-filled circles are adult haematopoietic stem 
cells and adult blood cells, respectively. Here, for simplicity, we assumed a 
uniform mutation rate of one substitution per cell per cell doubling. Each 
mutation during cell doubling is represented by a number in a black-filled 
rectangle. Mutations accumulated in a specific early cell are shown with 
numbers next to the cell. The final mutations acquired at an early cell of 
cell generation IV (16-cell stage) and their expected relative contribution 
to adult blood tissues (1 out of 16 or 6.6%) is summarized in the box below 
the cellular phylogenetic tree. We assumed that breast cancer (green-filled 
circles) cells are descended from the embryonic cell of the leftmost lineage 
(which has mutations 1, 3, 7 and 15). In the circumstances, the expected 
features of early embryonic mutations (VAFs, chance to be shared with 
breast cancer) are summarized in the right table. b, An alternative scenario 
with a neoplastic clonal expansion in the blood (here we assumed a 
haematopoietic stem cell contributes 40% of all blood cells). We assumed 
that additional 100 somatic mutations were further acquired during late 
cell doublings. The expected features are summarized in the right table.
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Extended Data Figure 4 | Features of mutations in blood samples with 
neoplastic clonal expansions. Mutations from samples with evidence of 
neoplastic clonal expansions display more similar VAFs to (the right violin 
plot) each other compared to mutations from samples without neoplastic 
clonal expansions (the left violin plot).
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Extended Data Figure 5 | Features of the early embryonic mutations 
identified in this study. a, As expected for early embryonic mutations, we 
observe no relationship between the age of individuals and the number of 
mutations found in an individual. In case of late mutations, we find more 
mutations in the aged individuals (Fig. 1f). b, Features of mutations in the 
samples (n = 7) with four early embryonic mutations suggest that these 
mutations are not likely to be related with a neoplastic clonal expansion: 
VAFs of mutations are diverse and a fraction of these mutations are 
shared with the matched cancer. The corresponding VAFs in the matched 
tumour tissues are shown in numbers above the bars. c, Samples with 
neoplastic clonal expansions (that is, PD9568b, PD9752b and PD9569b) 
show different features: mutations show similar VAFs each other and are 
not shared by cancer cells. d, Enrichment of early mutations according to 
ENCODE dataset. We find higher mutation frequency in transcriptionally 
repressed (R) than active (T) regions, but the difference is non-significant 
in our study (χ2 test, degrees of freedom = 1, P value = 0.4696), 
presumably due to the insufficient number of early embryonic mutations 
(n = 163). R, repressed chromatin; T, transcribed chromatin; CTCF, 
CTCF-bound regions; E, enhancer related; TSS/PF, promoter related.  
e, From a simulation study using 1,000 in silico embryonic mutations, 
we assessed the detection sensitivity of early embryonic mutations from 
32× whole-genome sequencing (see Methods). This sensitivity was used 
in downstream analyses (for example, likelihood tests for understanding 
the asymmetry of cell doublings and tests for the calculation of the early 
embryonic mutation rates. Error bars denote 95% confidence interval 
using exact Poisson tests.
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Extended Data Figure 6 | Expected proportion of early embryonic 
mutations shared by cancer according to the cell generation gap 
between the MRCA cell of adult blood cells and the MRCA cell of all 
somatic cells. See Supplementary Discussion 4. a, A scenario in which 
there is no cell generation gap. Early mutations are represented by asterisks 
in colours. A summary of the expected proportion of mutations shared 
with cancer cells is shown in the table: the chance is twice the VAF of each 
early embryonic mutation. b, A scenario in which the MRCA cell of adult 
blood cells is formed one cell generation later than the MRCA cell of all 
somatic cells. The chance is identical to the VAF of each early embryonic 
mutation. c, A scenario in which the MRCA cell of adult blood cells is 
formed two cell generations later than the MRCA cell of all somatic cells. 
The chance is half the VAF of each early embryonic mutation.
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Extended Data Figure 7 | The MRCA cell of adult blood cells is the 
MRCA cell of all somatic cells (or the fertilized egg). See Supplementary 
Discussion 4. Using the expected proportion of mutations shared with 
cancer (Extended Data Fig. 6), we estimated the timing when the MRCA 
cell of adult blood cells is formed. The four orange boxes show the 
expected proportions from four scenarios, when there are 0, 1, 2 and  
3 cell generation gaps between the MRCA cells. The observed proportion 
(26%; green horizontal line) in this study is closest to the expectation from 
the model of 0 cell generation gap. Error bars are interquartile range × 2 
(from the simulation study).
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Extended Data Figure 8 | The simulation study to understand potential 
stochasticity in the embryoblast formation. See Methods, ‘A stochastic 
model of embryoblast formation’ for more details. a, The expected 
distribution of VAF of early embryonic mutations in a stochastic model in 
which n cells (y axis) are randomly selected as epiblasts from the 32-cell 
stage embryo. The size of circle is proportional to the relative frequency of 
mutations at each VAF. b, The stochastic model estimates the number of 
founder epiblast cells and the timing (cell stage) of their commitment. The 
maximum likelihood is selection of 11 cells in 64-cell stage. c, The VAF 
distribution of early embryonic mutations expected from the maximum 
likelihood stochastic model. The maximum likelihood estimation 
(MLE) and the posterior probability by a Bayesian approach are shown 
by green and purple curves, respectively. Our observation of the 163 
early embryonic mutations is represented by the histogram. d, Unequal 
contribution of the first two cells to ICM cells by direct observation of 
12 mouse-embryos using inverted light-sheet microscope (see ref. 19). 
Schematic diagram (cell phylogeny) is shown above the bar graph. We 
reanalysed their observation, counting the relative contribution to ICM 
(black dots indicate the observed asymmetry in each embryo). These 
unequal contribution levels ranged from 0.5:0.5 to 0.74:0.26 and the 
average was 0.6:0.4.
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Extended Data Figure 9 | Early embryonic mutations (n = 7) identified 
from three large families. a–g, Sequencing reads (using IGV images) 
for the seven mutation loci are shown. All mutations are subclonal to a 
specific allele of a heterozygous SNP in the vicinity. As expected for early 
embryonic mutations, the VAFs of mutant alleles are lower than 0.5 and 
the mutant alleles are not found in the genomes of all the parents and the 
siblings. It was possible to perform ultrahigh-depth targeted amplicon 
sequencing (by MiSeq) on three mutations, and all were successfully 
validated.
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Extended Data Figure 10 | Signatures of early embryonic mutations.  
a, The mutational spectrum for 163 early embryonic mutations 
is displayed according to the 96 substitution classes (defined by 6 
substitution classes (C> A, C> G, C> T, T> A, T> C, T> G) and 16 
sequence contexts (immediate 5′ and 3′ bases to the mutated pyrimidine 
bases; see ref. 7 for more details). The observed spectrum can be 
decomposed into two known mutational signatures (signatures 5 and 1),  
suggesting that endogenous mutational processes are dominantly 
operative in early human embryogenesis (see Supplementary Discussion 
6 for more details). b, The methylation status of 28 C> T early embryonic 
mutations occurred at NpCpG sequence contexts. Methylation levels were 
obtained from a previous report38. The vast majority of the 28 loci were 
methylated, which is higher than background (right).
